Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review

Journal of Autoimmunity

Volumn 83, Issue , 2017, Pages 1-11

  Chen, Kun ^a   Liu, Juan ^b   Cao, Xuetao ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Autoimmune diseases; Epigenetic modification; Innate immunity; Interferon; Post translational modification

Indexed keywords

INTERFERON; LONG UNTRANSLATED RNA; MICRORNA; UNTRANSLATED RNA;

AUTOIMMUNE DISEASE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; HISTONE MODIFICATION; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; MYOSITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SUMOYLATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UBIQUITINATION; VIRUS INFECTION; ANIMAL; GENETIC EPIGENESIS; HOMEOSTASIS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM;

ANIMALS; AUTOIMMUNE DISEASES; EPIGENESIS, GENETIC; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFLAMMATION; INTERFERON TYPE I; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 85015800274     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2017.03.008     Document Type: Review

References (114)

1. Isaacs, A., Lindenmann, J., Virus interference. I. The interferon. Proc. R. Soc. Lond. B. Biol. Sci. 147 (1957), 258–267.
2. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., O'Garra, A., Type I interferons in infectious disease. Nat. Rev. Immunol. 15 (2015), 87–103.
3. Xing, J., Weng, L., Yuan, B., Wang, Z., Jia, L., Jin, R., et al. Identification of a role for TRIM29 in the control of innate immunity in the respiratory tract. Nat. Immunol. 17 (2016), 1373–1380.
4. Li, S., Zhu, M., Pan, R., Fang, T., Cao, Y.Y., Chen, S., et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat. Immunol. 17 (2016), 241–249.
5. Wang, F., Alain, T., Szretter, K.J., Stephenson, K., Pol, J.G., Atherton, M.J., et al. S6K-STING interaction regulates cytosolic DNA-mediated activation of the transcription factor IRF3. Nat. Immunol. 17 (2016), 514–522.
6. Li, X., Zhang, Q., Shi, Q., Liu, Y., Zhao, K., Shen, Q., et al. Demethylase Kdm6a epigenetically promotes IL-6 and IFN-beta production in macrophages. J. Autoimmun., 2017 pii: S0896-8411(16)30360-2.
7. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
8. Stark, G.R., Darnell, J.E. Jr., The JAK-STAT pathway at twenty. Immunity 36 (2012), 503–514.
9. Schneider, W.M., Chevillotte, M.D., Rice, C.M., Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32 (2014), 513–545.
10. Cheon, H., Stark, G.R., Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 9373–9378.
11. Blaszczyk, K., Nowicka, H., Kostyrko, K., Antonczyk, A., Wesoly, J., Bluyssen, H.A., The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 29 (2016), 71–81.
12. Katsoulidis, E., Li, Y., Mears, H., Platanias, L.C., The p38 mitogen-activated protein kinase pathway in interferon signal transduction. J. Interferon Cytokine Res. 25 (2005), 749–756.
13. Wang, F., Ma, Y., Barrett, J.W., Gao, X., Loh, J., Barton, E., et al. Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat. Immunol. 5 (2004), 1266–1274.
14. Saleiro, D., Platanias, L.C., Intersection of mTOR and STAT signaling in immunity. Trends Immunol. 36 (2015), 21–29.
15. Gonzalez-Navajas, J.M., Lee, J., David, M., Raz, E., Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12 (2012), 125–135.
16. Moro, K., Kabata, H., Tanabe, M., Koga, S., Takeno, N., Mochizuki, M., et al. Interferon and IL-27 antagonize the function of group 2 innate lymphoid cells and type 2 innate immune responses. Nat. Immunol. 17 (2016), 76–86.
17. Duerr, C.U., McCarthy, C.D., Mindt, B.C., Rubio, M., Meli, A.P., Pothlichet, J., et al. Type I interferon restricts type 2 immunopathology through the regulation of group 2 innate lymphoid cells. Nat. Immunol. 17 (2016), 65–75.
18. Huber, J.P., Farrar, J.D., Regulation of effector and memory T-cell functions by type I interferon. Immunology 132 (2011), 466–474.
19. Liu, J., Cao, X., Cellular and molecular regulation of innate inflammatory responses. Cell. Mol. Immunol. 13 (2016), 711–721.
20. Mostafavi, S., Yoshida, H., Moodley, D., LeBoite, H., Rothamel, K., Raj, T., et al. Parsing the interferon transcriptional network and its disease associations. Cell 164 (2016), 564–578.
21. van Boxel-Dezaire, A.H., Rani, M.R., Stark, G.R., Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25 (2006), 361–372.
22. Mowen, K.A., David, M., Unconventional post-translational modifications in immunological signaling. Nat. Immunol. 15 (2014), 512–520.
23. Liu, J., Qian, C., Cao, X., Post-translational modification control of innate immunity. Immunity 45 (2016), 15–30.
24. Levy, D.E., Darnell, J.E. Jr., Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3 (2002), 651–662.
25. Wen, Z., Zhong, Z., Darnell, J.E. Jr., Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82 (1995), 241–250.
26. Uddin, S., Sassano, A., Deb, D.K., Verma, A., Majchrzak, B., Rahman, A., et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J. Biol. Chem. 277 (2002), 14408–14416.
27. Putz, E.M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 4 (2013), 437–444.
28. Tenoever, B.R., Ng, S.L., Chua, M.A., McWhirter, S.M., Garcia-Sastre, A., Maniatis, T., Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 315 (2007), 1274–1278.
29. Wang, Y., Nan, J., Willard, B., Wang, X., Yang, J., Stark, G.R., Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387. EMBO J. 36 (2017), 202–212.
30. Shuai, K., Liu, B., Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3 (2003), 900–911.
31. Fenner, J.E., Starr, R., Cornish, A.L., Zhang, J.G., Metcalf, D., Schreiber, R.D., et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat. Immunol. 7 (2006), 33–39.
32. Du, Z., Shen, Y., Yang, W., Mecklenbrauker, I., Neel, B.G., Ivashkiv, L.B., Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 102 (2005), 10267–10272.
33. Mustelin, T., Vang, T., Bottini, N., Protein tyrosine phosphatases and the immune response. Nat. Rev. Immunol. 5 (2005), 43–57.
34. Wu, T.R., Hong, Y.K., Wang, X.D., Ling, M.Y., Dragoi, A.M., Chung, A.S., et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. J. Biol. Chem. 277 (2002), 47572–47580.
35. Jiang, X., Chen, Z.J., The role of ubiquitylation in immune defence and pathogen evasion. Nat. Rev. Immunol. 12 (2011), 35–48.
36. Song, G., Liu, B., Li, Z., Wu, H., Wang, P., Zhao, K., et al. E3 ubiquitin ligase RNF128 promotes innate antiviral immunity through K63-linked ubiquitination of TBK1. Nat. Immunol. 17 (2016), 1342–1351.
37. Torre, S., Polyak, M.J., Langlais, D., Fodil, N., Kennedy, J.M., Radovanovic, I., et al. USP15 regulates type I interferon response and is required for pathogenesis of neuroinflammation. Nat. Immunol. 18 (2017), 54–63.
38. Kumar, K.G., Tang, W., Ravindranath, A.K., Clark, W.A., Croze, E., Fuchs, S.Y., SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 22 (2003), 5480–5490.
39. Tanaka, T., Soriano, M.A., Grusby, M.J., SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22 (2005), 729–736.
40. Yuan, C., Qi, J., Zhao, X., Gao, C., Smurf1 protein negatively regulates interferon-gamma signaling through promoting STAT1 protein ubiquitination and degradation. J. Biol. Chem. 287 (2012), 17006–17015.
41. Ren, Y., Zhao, P., Liu, J., Yuan, Y., Cheng, Q., Zuo, Y., et al. Deubiquitinase USP2a sustains interferons antiviral activity by restricting ubiquitination of activated STAT1 in the nucleus. PLoS Pathog., 12, 2016, e1005764.
42. Lawrence, D.W., Kornbluth, J., E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity. Cell. Signal 28 (2016), 1833–1841.
43. Melchior, F., SUMO–nonclassical ubiquitin. Annu. Rev. Cell Dev. Biol. 16 (2000), 591–626.
44. Durfee, L.A., Lyon, N., Seo, K., Huibregtse, J.M., The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell 38 (2010), 722–732.
45. Ungureanu, D., Vanhatupa, S., Gronholm, J., Palvimo, J.J., Silvennoinen, O., SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 106 (2005), 224–226.
46. Liu, B., Mink, S., Wong, K.A., Stein, N., Getman, C., Dempsey, P.W., et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat. Immunol. 5 (2004), 891–898.
47. Maarifi, G., Maroui, M.A., Dutrieux, J., Dianoux, L., Nisole, S., Chelbi-Alix, M.K., Small ubiquitin-like modifier alters IFN response. J. Immunol. 195 (2015), 2312–2324.
48. Scherer, M., Stamminger, T., Emerging role of PML nuclear bodies in innate immune signaling. J. Virol. 90 (2016), 5850–5854.
49. Malakhova, O.A., Yan, M., Malakhov, M.P., Yuan, Y., Ritchie, K.J., Kim, K.I., et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes Dev. 17 (2003), 455–460.
50. Skaug, B., Chen, Z.J., Emerging role of ISG15 in antiviral immunity. Cell 143 (2010), 187–190.
51. Malakhov, M.P., Kim, K.I., Malakhova, O.A., Jacobs, B.S., Borden, E.C., Zhang, D.E., High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem. 278 (2003), 16608–16613.
52. Ritchie, K.J., Hahn, C.S., Kim, K.I., Yan, M., Rosario, D., Li, L., et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat. Med. 10 (2004), 1374–1378.
53. Lai, C., Struckhoff, J.J., Schneider, J., Martinez-Sobrido, L., Wolff, T., Garcia-Sastre, A., et al. Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouse-adapted and non-mouse-adapted influenza B virus infection. J. Virol. 83 (2009), 1147–1151.
54. Yang, X.J., Seto, E., Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol. Cell 31 (2008), 449–461.
55. Li, X., Zhang, Q., Ding, Y., Liu, Y., Zhao, D., Zhao, K., et al. Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity. Nat. Immunol. 17 (2016), 806–815.
56. Tang, X., Gao, J.S., Guan, Y.J., McLane, K.E., Yuan, Z.L., Ramratnam, B., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 131 (2007), 93–105.
57. Kramer, O.H., Knauer, S.K., Greiner, G., Jandt, E., Reichardt, S., Guhrs, K.H., et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes Dev. 23 (2009), 223–235.
58. Mowen, K.A., Tang, J., Zhu, W., Schurter, B.T., Shuai, K., Herschman, H.R., et al. Arginine methylation of STAT1 modulates IFNalpha/beta-induced transcription. Cell 104 (2001), 731–741.
59. Chen, T., Dent, S.Y., Chromatin modifiers and remodellers: regulators of cellular differentiation. Nat. Rev. Genet. 15 (2014), 93–106.
60. Holoch, D., Moazed, D., RNA-mediated epigenetic regulation of gene expression. Nat. Rev. Genet. 16 (2015), 71–84.
61. Alvarez-Errico, D., Vento-Tormo, R., Sieweke, M., Ballestar, E., Epigenetic control of myeloid cell differentiation, identity and function. Nat. Rev. Immunol. 15 (2015), 7–17.
62. Cao, X., Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat. Rev. Immunol. 16 (2016), 35–50.
63. Decque, A., Joffre, O., Magalhaes, J.G., Cossec, J.C., Blecher-Gonen, R., Lapaquette, P., et al. Sumoylation coordinates the repression of inflammatory and anti-viral gene-expression programs during innate sensing. Nat. Immunol. 17 (2016), 140–149.
64. Meng, J., Liu, X., Zhang, P., Li, D., Xu, S., Zhou, Q., et al. Rb selectively inhibits innate IFN-beta production by enhancing deacetylation of IFN-beta promoter through HDAC1 and HDAC8. J. Autoimmun. 73 (2016), 42–53.
65. Paulson, M., Press, C., Smith, E., Tanese, N., Levy, D.E., IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat. Cell Biol. 4 (2002), 140–147.
66. Patel, M.C., Debrosse, M., Smith, M., Dey, A., Huynh, W., Sarai, N., et al. BRD4 coordinates recruitment of pause release factor P-TEFb and the pausing complex NELF/DSIF to regulate transcription elongation of interferon-stimulated genes. Mol. Cell. Biol. 33 (2013), 2497–2507.
67. Vahedi, G., Takahashi, H., Nakayamada, S., Sun, H.W., Sartorelli, V., Kanno, Y., et al. STATs shape the active enhancer landscape of T cell populations. Cell 151 (2012), 981–993.
68. Ostuni, R., Piccolo, V., Barozzi, I., Polletti, S., Termanini, A., Bonifacio, S., et al. Latent enhancers activated by stimulation in differentiated cells. Cell 152 (2013), 157–171.
69. Chang, H.M., Paulson, M., Holko, M., Rice, C.M., Williams, B.R., Marie, I., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc. Natl. Acad. Sci. U.S.A. 101 (2004), 9578–9583.
70. Gao, B., Duan, Z., Xu, W., Xiong, S., Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 50 (2009), 424–433.
71. Fang, T.C., Schaefer, U., Mecklenbrauker, I., Stienen, A., Dewell, S., Chen, M.S., et al. Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response. J. Exp. Med. 209 (2012), 661–669.
72. Singh, N., Ramijrez-Carvajal, L., de Los Santos, T., Golding, M.C., Long, C.R., Inhibition of EHMT2 induces a robust antiviral response against foot-and-mouth disease and vesicular stomatitis virus infections in bovine cells. J. Interferon Cytokine Res. 36 (2016), 37–47.
73. Kroetz, D.N., Allen, R.M., Schaller, M.A., Cavallaro, C., Ito, T., Kunkel, S.L., Type I interferon induced epigenetic regulation of macrophages suppresses innate and adaptive immunity in acute respiratory viral infection. PLoS Pathog., 11, 2015, e1005338.
74. Fonseca, G.J., Thillainadesan, G., Yousef, A.F., Ablack, J.N., Mossman, K.L., Torchia, J., et al. Adenovirus evasion of interferon-mediated innate immunity by direct antagonism of a cellular histone posttranslational modification. Cell Host Microbe 11 (2012), 597–606.
75. Zhang, Y., Mao, D., Roswit, W.T., Jin, X., Patel, A.C., Patel, D.A., et al. PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection. Nat. Immunol. 16 (2015), 1215–1227.
76. Trotter, K.W., Archer, T.K., Nuclear receptors and chromatin remodeling machinery. Mol. Cell. Endocrinol. 265–266 (2007), 162–167.
77. Huang, M., Qian, F., Hu, Y., Ang, C., Li, Z., Wen, Z., Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat. Cell Biol. 4 (2002), 774–781.
78. Liu, H., Kang, H., Liu, R., Chen, X., Zhao, K., Maximal induction of a subset of interferon target genes requires the chromatin-remodeling activity of the BAF complex. Mol. Cell. Biol. 22 (2002), 6471–6479.
79. Wu, H., Zhang, Y., Reversing DNA methylation: mechanisms, genomics, and biological functions. Cell 156 (2014), 45–68.
80. + T cells from lupus patients. J. Autoimmun. 43 (2013), 78–84.
81. Coit, P., Yalavarthi, S., Ognenovski, M., Zhao, W., Hasni, S., Wren, J.D., et al. Epigenome profiling reveals significant DNA demethylation of interferon signature genes in lupus neutrophils. J. Autoimmun. 58 (2015), 59–66.
82. Kohli, R.M., Zhang, Y., TET enzymes, TDG and the dynamics of DNA demethylation. Nature 502 (2013), 472–479.
83. Zhang, Q., Zhao, K., Shen, Q., Han, Y., Gu, Y., Li, X., et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525 (2015), 389–393.
84. Yang, R., Qu, C., Zhou, Y., Konkel, J.E., Shi, S., Liu, Y., et al. Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity 43 (2015), 251–263.
85. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15 (2014), 509–524.
86. Papadopoulou, A.S., Dooley, J., Linterman, M.A., Pierson, W., Ucar, O., Kyewski, B., et al. The thymic epithelial microRNA network elevates the threshold for infection-associated thymic involution via miR-29a mediated suppression of the IFN-alpha receptor. Nat. Immunol. 13 (2011), 181–187.
87. Wang, P., Hou, J., Lin, L., Wang, C., Liu, X., Li, D., et al. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J. Immunol. 185 (2010), 6226–6233.
88. Kohanbash, G., Okada, H., MicroRNAs and STAT interplay. Semin. Cancer Biol. 22 (2012), 70–75.
89. Mukherjee, A., Di Bisceglie, A.M., Ray, R.B., Hepatitis C virus-mediated enhancement of microRNA miR-373 impairs the JAK/STAT signaling pathway. J. Virol. 89 (2015), 3356–3365.
90. Bhanja Chowdhury, J., Shrivastava, S., Steele, R., Di Bisceglie, A.M., Ray, R., Ray, R.B., Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J. Virol. 86 (2012), 10221–10225.
91. Hao, J., Jin, W., Li, X., Wang, S., Zhang, X., Fan, H., et al. Inhibition of alpha interferon (IFN-alpha)-induced microRNA-122 negatively affects the anti-hepatitis B virus efficiency of IFN-alpha. J. Virol. 87 (2013), 137–147.
92. Maass, P.G., Luft, F.C., Bahring, S., Long non-coding RNA in health and disease. J. Mol. Med. (Berl.) 92 (2014), 337–346.
93. Heward, J.A., Lindsay, M.A., Long non-coding RNAs in the regulation of the immune response. Trends Immunol. 35 (2014), 408–419.
94. Geisler, S., Coller, J., RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14 (2013), 699–712.
95. Morris, K.V., Mattick, J.S., The rise of regulatory RNA. Nat. Rev. Genet. 15 (2014), 423–437.
96. Atianand, M.K., Fitzgerald, K.A., Long non-coding RNAs and control of gene expression in the immune system. Trends Mol. Med. 20 (2014), 623–631.
97. Wang, P., Xue, Y., Han, Y., Lin, L., Wu, C., Xu, S., et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. Science 344 (2014), 310–313.
98. Josset, L., Tchitchek, N., Gralinski, L.E., Ferris, M.T., Eisfeld, A.J., Green, R.R., et al. Annotation of long non-coding RNAs expressed in collaborative cross founder mice in response to respiratory virus infection reveals a new class of interferon-stimulated transcripts. RNA Biol. 11 (2014), 875–890.
99. Kambara, H., Niazi, F., Kostadinova, L., Moonka, D.K., Siegel, C.T., Post, A.B., et al. Negative regulation of the interferon response by an interferon-induced long non-coding RNA. Nucleic Acids Res. 42 (2014), 10668–10680.
100. Gomez, J.A., Wapinski, O.L., Yang, Y.W., Bureau, J.F., Gopinath, S., Monack, D.M., et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. Cell 152 (2013), 743–754.
101. Ouyang, J., Zhu, X., Chen, Y., Wei, H., Chen, Q., Chi, X., et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe 16 (2014), 616–626.
102. Barriocanal, M., Carnero, E., Segura, V., Fortes, P., Long non-coding RNA BST2/BISPR is induced by IFN and regulates the expression of the antiviral factor tetherin. Front. Immunol., 5, 2014, 655.
103. Carpenter, S., Aiello, D., Atianand, M.K., Ricci, E.P., Gandhi, P., Hall, L.L., et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science 341 (2013), 789–792.
104. Atianand, M.K., Hu, W., Satpathy, A.T., Shen, Y., Ricci, E.P., Alvarez-Dominguez, J.R., et al. A long noncoding RNA lincRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell 165 (2016), 1672–1685.
105. Hall, J.C., Rosen, A., Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol. 6 (2010), 40–49.
106. Kalliolias, G.D., Ivashkiv, L.B., Overview of the biology of type I interferons. Arthritis Res. Ther., 12(Suppl 1), 2010, S1.
107. Henault, J., Riggs, J.M., Karnell, J.L., Liarski, V.M., Li, J., Shirinian, L., et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. Nat. Immunol. 17 (2016), 196–203.
108. Nacionales, D.C., Kelly-Scumpia, K.M., Lee, P.Y., Weinstein, J.S., Lyons, R., Sobel, E., et al. Deficiency of the type I interferon receptor protects mice from experimental lupus. Arthritis Rheum. 56 (2007), 3770–3783.
109. Yao, Y., Richman, L., Higgs, B.W., Morehouse, C.A., de los Reyes, M., Brohawn, P., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60 (2009), 1785–1796.
110. Lu, X., Tang, Q., Lindh, M., Dastmalchi, M., Alexanderson, H., Popovic Silwerfeldt, K., et al. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis. J. Autoimmun. 78 (2017), 46–56.
111. Wilson, E.B., Yamada, D.H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340 (2013), 202–207.
112. Teijaro, J.R., Ng, C., Lee, A.M., Sullivan, B.M., Sheehan, K.C., Welch, M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340 (2013), 207–211.
113. Fallet, B., Narr, K., Ertuna, Y.I., Remy, M., Sommerstein, R., Cornille, K., et al. Interferon-driven deletion of antiviral B cells at the onset of chronic infection. Sci. Immunol., 1, 2016, eaah6817.
114. Benci, J.L., Xu, B., Qiu, Y., Wu, T.J., Dada, H., Twyman-Saint Victor, C., et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167 (2016), 1540–1554.